AMERI_1170x120_11-6-20

Dr. Reddy’s Laboratories

Dr. Reddy’s offers timely and proactive initiatives

Dr. Reddy’s offers timely and proactive initiatives

PRINCETON, N.J. — Dr. Reddy’s path to excelling in the manufacture of complex generics and biosimilars depends on its successful filing for new drugs — be these formulations or active pharmaceutical ingredients (APIs). In fiscal 2020, the company filed eight new Abbreviated New Drug Applications (ANDAs) with the Food and Drug Administration. As of March

Dr. Reddy’s rolls out generic version of Ciprodex

Dr. Reddy’s rolls out generic version of Ciprodex

PRINCETON, N.J. – Dr. Reddy’s  announced the launch of ciprofloxacin 0.3% and dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring

Brill: Dr. Reddy’s meeting challenges

Brill: Dr. Reddy’s meeting challenges

PRINCETON, N.J. — When the COVID-19 pandemic hit, the generic drug industry faced many challenges, says Vanessa Brill, vice president and regional general counsel for the Americas at Dr. Reddy’s Laboratories. For Dr. Reddy’s, the challenges included finding ways to continue to produce drugs at manufacturing facilities that had to operate at decreased capacity out

Dr. Reddy’s enters into a licensing agreement with Gilead Sciences for Remdesivir

Dr. Reddy’s enters into a licensing agreement with Gilead Sciences for Remdesivir

PRINCETON, N.J.— Dr. Reddy’s announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this

Dr. Reddy’s gets approval for their NDA, Elyxyb (celecoxib oral solution) 25 mg/mL, in the U.S.

Dr. Reddy’s gets approval for their NDA, Elyxyb (celecoxib oral solution) 25 mg/mL, in the U.S.

PRINCETON, N.J. —Dr. Reddy’s announced approval of Elyxyb (celecoxib oral solution 25 mg/mL) by the U.S. Food and Drug Administration (USFDA). Elyxyb (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. Elyxyb is the latest product emerging from Dr. Reddy’s portfolio of successful acute migraine treatments.

Dr. Reddy’s Laboratories announces the launch of desmopressin acetate injection

Dr. Reddy’s Laboratories announces the launch of desmopressin acetate injection

PRINCETON, N.J. — Dr. Reddy’s announced the launch of desmopressin acetate injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA). The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9

Dr. Reddy’s rolls out pre-filled naloxone syringes

Dr. Reddy’s rolls out pre-filled naloxone syringes

PRINCETON,  N.J.— Dr. Reddy’s Laboratories announced Monday the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring our second product to market that has been

Upsher-Smith acquires two products from Dr. Reddy’s

Upsher-Smith acquires two products from Dr. Reddy’s

MAPLE GROVE, Minn. – Upsher-Smith recently announced that it has completed the acquisition of Tosymra (sumatriptan) Nasal Spray, 10 mg, and Zembrace SymTouch (sumatriptan) Injection 3 mg from Dr. Reddy’s Laboratories. The products were previously commercialized through Dr. Reddy’s wholly owned subsidiary, Promius Pharma. Both medications are indicated for the acute treatment of migraine with

Dr. Reddy’s gets FDA approval for Tosymra

Dr. Reddy’s gets FDA approval for Tosymra

PRINCETON, N.J. — Dr. Reddy’s Laboratories and its subsidiary, Promius Pharma. today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute treatment of migraine with or without aura in adults. Tosymra is the latest product to join the Promius Pharma acute migraine treatment

Dr. Reddy’s launches sevelamer carbonate for oral suspension in U.S.

Dr. Reddy’s launches sevelamer carbonate for oral suspension in U.S.

PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of sevelamer carbonate for oral suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the U.S. Food and Drug Administration. The Renvela brand and generic had U.S. sales of approximately $101 million MAT

Dr. Reddy’s rolls out aspirin and extended-release dipyridamole capsules

Dr. Reddy’s rolls out aspirin and extended-release dipyridamole capsules

PRINCETON, N.J. — Dr. Reddy’s Laboratories Ltd. recently announced the launch of aspirin and extended-release dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules in the United States market from the U.S. Food and Drug Administration. The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for

Dr. Reddy’s releases generic version of Strattera

Dr. Reddy’s releases generic version of Strattera

HYDERABAD, India and PRINCETON, N.J . — Dr. Reddy’s Laboratories announced the roll out of its atomoxetine capsules. The product is for the treatment of attention-deficit/hyperactivity disorder, is a generic version of Eli Lilly’s Strattera. Dr. Reddy’s atomoxetine capsules are available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100

Dr. Reddy’s receives approval for aspirin and extended-release dipyridamole capsules

Dr. Reddy’s receives approval for aspirin and extended-release dipyridamole capsules

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories  announced receipt of approval for aspirin and extended-release dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration. The company is working towards launching the product. The Aggrenox brand and

Dr. Reddy’s rolls out generic of Plaquenil

Dr. Reddy’s rolls out generic of Plaquenil

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of hydroxychloroquine sulfate tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil (hydroxychloroquine sulfate) tablets, in the U.S. market, approved by the U.S. Food and Drug Administration. The Plaquenil brand and generic had U.S. sales of approximately $215 million MAT for